The prototypical irreversible Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is currently approved for all patients with CLL on the basis of the results of the RESONATE35, RESONATE-236, and RESONATE-1737 trials. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.